NEW YORK, July 30, 2024 /PRNewswire/ — Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New…
Month: July 2024
NEW YORK, July 30, 2024 /PRNewswire/ — Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New…
NEW YORK, July 30, 2024 /PRNewswire/ — Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New…
NEW YORK, July 30, 2024 /PRNewswire/ — Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New…
In its opinion, the Court of Appeals of Virginia fundamentally misread and misapplied precedent from the Supreme Court of Virginia and failed to give due regard to the trial judge’s evidentiary determinations and trial misconduct by Pegasystems MCLEAN, Va., July 30, 2024 /PRNewswire/ –…
OTTAWA, ON and WASHINGTON , July 30, 2024 /PRNewswire/ — The International Joint Commission (IJC) will host a one-hour public webinar related to the study of transboundary water pollution in the Elk-Kootenai/y watershed on Tuesday, August 6, at 6:30 p.m. MDT (5:30 pm. PDT). All…
WASHINGTON, July 30, 2024 /PRNewswire/ — In advance of Allegiant Travel Company’s Allegiant (NASDAQ: ALGT) 2024 second-quarter earnings announcement tomorrow, Allegiant Air pilots and their union are raising questions about the company’s direction and decision-making as pilots continue…
INCHEON, South Korea, July 30, 2024 /PRNewswire/ — Zymedi (CEO Sunghoon Kim) announced that its first-in-class antibody treatment ZMA001, currently in development for pulmonary arterial hypertension (PAH), has been designated as an Orphan Drug by the U.S. Food and Drug Administration…
